United Therapeutics Corporation (NASDAQ:UTHR) surged 0.31% during the last session. The last traded price was up 0.33 points at $106.61. The data for the fund flow suggests that the net intraday money flow was $(-6.45) million. The fund value in upticks was recorded to be $0.32 million and in downticks, it was found to be $6.77 million. The up/down ratio for the day was measured to be 0.05. For the week, the shares have seen a percentage change of -4.26%.A block trade of $(-6.48) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $0 million and that of downticks was $6.48 million. The block tradeoff had the up/down ratio of 0.
United Therapeutics Corporation has lost 8.3% in the last five trading days and dropped 9.2% in the last 4 weeks. United Therapeutics Corporation has dropped 16.83% during the last 3-month period . Year-to-Date the stock performance stands at -34.8%.
Currently the company Insiders own 8.5% of United Therapeutics Corporation shares according to the proxy statements. . On the companys insider trading activities, The Securities and Exchange Commission has divulged that Rothblatt Martine A, director officer (Chairman & Co-CEO) of United Therapeutics Corp, had unloaded 1,308 shares at an average price of $105 in a transaction dated on June 16, 2016. The total value of the transaction was worth $137,340.
United Therapeutics Corporation (NASDAQ:UTHR) witnessed a decline in the market cap on Friday as its shares dropped 3.92% or 4.17 points. After the session commenced at $106, the stock reached the higher end at $107.49 while it hit a low of $101.47. With the volume soaring to 963,362 shares, the last trade was called at $102.11. The company has a 52-week high of $190.13. The company has a market cap of $4,556 million and there are 44,621,988 shares in outstanding. The 52-week low of the share price is $101.47.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.